|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Recombinant Human HGFA protein (Catalog#10329-H08H)|
|0.2 μm filtered solution in PBS with 5% trehalose|
|This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human HGFA (rhHGFA; Catalog#10329-H08H; NP_001519.1; Met 1-Ser 655). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.|
|Human HGFA / HGF activator|
ELISA: 0.5-1 μg/mL
This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect HGFA. The detection limit for HGFA is approximately 0.625 ng/well.
|This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.|
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
HGF activator (HGFA) is a serum-derived serine protease and belongs to the peptidase family S1.HGFA is responsible for the conversion of hepatocyte growth factor (HGF), from the inactive single-chain precursor to the active heterodimeric form, which is a potent mitogen, motogen, and morphogen for liver cells, epithelial cells, and endothelial cells. HGFA is synthesized and secreted by the liver and circulates in the plasma as an inactive single-chain zymogen in normal states. The zymogen is cleaved by thrombin or thermolysin through the endoproteolytic process and forms an active heterodimer linked by a disulfide bond. In turn, the active protease can be inhibited by HGFA inhibitors (HAIs) including HAI-1 and HAI-2. In addition, the HGFA zymogen acquires a strong affinity upon activation and thus may ensure the local action in tissue regeneration in liver, kidney and skin. It has been reported that activation of HGF is a critical limiting step in the HGF/SF-induced signaling pathway mediated by Met, and accordingly, aberrant expression of HGFA is implicated in tumorigenesis and progression.
1. Shimomura, T. et al., 1993, J. Biol. Chem. 268: 22927-22932.
2. Miyazawa, K. et al., 1996, J. Biol. Chem. 271 : 3615-3618.
3. Shia, S. et al., 2005, J. Mol. Biol. 346: 1335-1349.
4. Kataoka, H. et al., 2000, J. Biol. Chem. 275: 40453-40462.
5. Tjin, E.P. et al., 2006, Blood. 107: 760-768.
6. Kitajima, Y. et al., 2000, Cancer. Res. 60: 6148-6159.